# Physitrack Reports 14% Revenue Growth in Q3 as Shares Jump 10%

- URL: https://stocks.freetheai.org/news/physitrack-reports-14-revenue-growth-in-q3-as-shares-jump-10-a1aa75
- Published: 2026-10-20T06:00:00Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [OMXSTO:PTRK](https://stocks.freetheai.org/symbols/OMXSTO-PTRK)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Physitrack plc (OMXSTO:PTRK) reported third-quarter 2026 revenue of 3.6 million euros, an increase of 14% compared to the same period last year, or 11% on a constant currency basis. The healthcare technology business sustained profitability and cash generation, delivering adjusted EBITDA of 1.1 million euros at a 31% margin. Growth was primarily fueled by its core Lifecare division, which generated 3.3 million euros in revenue, up 15% year-over-year. Following the announcement, the company's stock jumped 10.00% to 12.1 SEK.

The operational results reflect stable customer retention and ongoing expansion in key markets. Physitrack maintained a net retention rate of 99.3% with low customer churn of 1.0%, helping secure its recurring revenue base. Commercial execution also advanced in North America, where two major US healthcare systems selected the company's platform, expanding its potential enterprise footprint.

Investors will look for signed enterprise contracts to convert into recognized revenue in upcoming quarters. Additionally, market participants will monitor the commercial rollout of Physitrack's electronic medical record system, which recently entered early access and is scheduled for full monetization starting in January 2027.

## Key points

- Q3 2026 revenue rose 14% year-over-year to 3.6 million euros, or 11% on a constant currency basis.
- Adjusted EBITDA reached 1.1 million euros, representing an adjusted EBITDA margin of 31%.
- The core Lifecare division generated 3.3 million euros in revenue, a 15% increase compared to the prior year.
- Physitrack achieved a net retention rate of 99.3% with a low monthly churn rate of 1.0%.
- Two US healthcare systems selected Physitrack, while its early access EMR platform prepares for monetization in January 2027.

## Questions and answers

### What were Physitrack's Q3 2026 financial results?

Physitrack reported Q3 2026 revenue of 3.6 million euros, up 14% year-over-year, and adjusted EBITDA of 1.1 million euros, delivering a 31% margin while remaining profitable and cash generative.

### How did Physitrack's Lifecare division perform in Q3 2026?

Physitrack's core Lifecare division generated 3.3 million euros in revenue during Q3 2026, representing a 15% increase compared to the prior-year period.

### What new developments did Physitrack announce in the US market?

Physitrack was selected by two US healthcare systems and launched its electronic medical record (EMR) system in early access, with monetization scheduled to begin in January 2027.